Unlike CLL cells that largely depend on the expression of BCL-2 alone, killing of most ALL xenografts required simultaneous inhibition of BCL-2 and BCL-XL, explaining the contrasting results obtained with venetoclax and navitoclax. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.